Brief: Newron: FDA considers re-submitted NDA for Xadago to be complete class 2 response to complete response letter
21/10/2016 06:00
Oct 21 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* US FDA considers newron's re-submitted NDA for Xadago to
be a complete, class 2 response to complete response letter
* User fee goal date (PDUFA date) to be March 21, 2017
Source text for Eikon: ID:nTENfn0w5a
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study